Induced pluripotent stem cells (iPSCs)
Sleep Disorder
University of Missouri-ColumbiaCell therapyActive
D
30/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 15/ 100
- Competitive Position
- 95/ 100
Competitive context
14 Active assets in the Sleep Disorder cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Trazodone Johns Hopkins University | Phase 4 | BB |
Armodafinil Cephalon | Phase 4 | BB |
Tvp-1012 Technische Universität Dresden | Phase 4 | BB |
MELATONIN Duke University | Phase 3 | BB |
Olanzapine Central Institute of Psychiatry, Ranchi, India | Phase 4 | BB |
View all 36 →
Same molecule, other indications
Induced pluripotent stem cells (iPSCs) is also rated in:
global developmental delay with or without impaired intellectual developmentDormant
D
Indicative ·
30 / 100
View asset →Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →